about
Hepatitis C virus induces the cannabinoid receptor 1.Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes.Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.Portal hypertension as immune mediate disease.Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation.Cannabinoid receptor type I modulates alcohol-induced liver fibrosis.Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysisCannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies?Update on the pathophysiology of liver fibrosis.Update on the endocannabinoid system as an anticancer target.Review article: the endocannabinoid system in liver disease, a potential therapeutic target.The peripheral cannabinoid receptor 1 antagonist VD60 efficiently inhibits carbon tetrachloride-intoxicated hepatic fibrosis progression.The direct profibrotic and indirect immune antifibrotic balance of blocking the cannabinoid 2 receptor.A case of cannabinoid hyperemesis syndrome with Heliobacter pylori and preeclampsia during pregnancy.The Role of Cannabinoids in the Setting of Cirrhosis.
P2860
Q33700418-C69A1510-7BA3-4569-8BEE-97629567189FQ34088634-D9FAE47C-0544-45FC-A93E-1896074CDDE4Q34537906-7B73276D-226A-4058-A420-8F0B2ECB5588Q34547759-AD58B1C5-F758-4716-93B3-4AFCBFA62B13Q34650930-4643D29C-8F05-410A-B2F6-4235E28DD0C4Q35197361-EAA4CAF2-424F-42EC-968D-371C25830676Q35585455-4F8AD4D3-0FFC-4FCD-B4DE-D46CEF49D053Q35876795-371BA856-6993-4A9D-9BB0-245338DA400EQ36026554-A3B576A0-E4E4-423F-9F10-752C097B28EBQ37085008-B8711258-7B5F-4604-8C8F-A6B9A0654BDFQ37546194-FA1296F2-19BF-45B4-A96A-EB5DAFFADF37Q37777155-267180B9-CC11-4BB0-9D56-9B764C723ECBQ37829751-1A662762-97C9-403F-9D2B-CCFF7AA25DC9Q38194626-15027E86-A1E6-467A-A9AB-EB4B688327B0Q39031169-78A9155B-9732-402B-84BB-C9665CEBF06BQ39361876-420CBF86-A8B9-4E74-AFD2-1C730E6B546CQ53570442-B6785DF5-BC20-4A83-9906-06541D14D202Q55415931-12FF7654-FE30-4EC5-AECA-8EB93927F7CA
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Role of cannabinoids in chronic liver diseases.
@en
Role of cannabinoids in chronic liver diseases.
@nl
type
label
Role of cannabinoids in chronic liver diseases.
@en
Role of cannabinoids in chronic liver diseases.
@nl
prefLabel
Role of cannabinoids in chronic liver diseases.
@en
Role of cannabinoids in chronic liver diseases.
@nl
P2860
P356
P1476
Role of cannabinoids in chronic liver diseases.
@en
P2093
Anna Parfieniuk
P2860
P304
P356
10.3748/WJG.14.6109
P407
P577
2008-10-01T00:00:00Z